List of Excipients in Branded Drug APTIOM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sumitomo Pharma America Inc	APTIOM	eslicarbazepine acetate	63402-202	CROSCARMELLOSE SODIUM
Sumitomo Pharma America Inc	APTIOM	eslicarbazepine acetate	63402-202	MAGNESIUM STEARATE
Sumitomo Pharma America Inc	APTIOM	eslicarbazepine acetate	63402-202	POVIDONE K30

APTIOM Excipient Strategy and Commercial Opportunities in Eslicarbazepine Acetate

Last updated: September 2, 2026

APTIOM is an immediate-release, oral tablet containing eslicarbazepine acetate for focal-onset seizures. Its commercial opportunity is shifting from basic generic substitution toward differentiated oral delivery, pediatric formulations, manufacturing efficiency, and excipient-enabled lifecycle products. The highest-value opportunities are pediatric liquid or multiparticulate products, orally disintegrating tablets, and robust low-cost tablet platforms that preserve the reference product's dissolution and bioequivalence profile.

What is APTIOM and how does its formulation work?

APTIOM contains eslicarbazepine acetate, a prodrug that is rapidly converted to eslicarbazepine after oral administration. The product is approved in the United States as once-daily tablets in 200 mg, 400 mg, 600 mg, and 800 mg strengths. It is indicated for the treatment of focal-onset seizures in patients at least four years of age, either as monotherapy or adjunctive therapy depending on the applicable labeling period and indication. [1]

The reference product is a conventional immediate-release tablet. Its formulation strategy prioritizes:

• High drug loading across 200 mg to 800 mg strengths
• Rapid tablet breakup and drug release
• Dose uniformity across multiple strengths
• Mechanical strength during coating, packaging, and distribution
• Chemical and physical stability
• A scalable manufacturing process suitable for commercial tablet production

The drug substance is not extremely low dose. This makes powder flow, segregation control, blend uniformity, compression behavior, and tablet weight control central to product performance.

What excipients are used in APTIOM tablets?

The APTIOM prescribing information identifies the following inactive ingredients:

Excipient	Primary formulation function
Microcrystalline cellulose	Diluent, compressibility enhancer, dry-binder
Croscarmellose sodium	Superdisintegrant
Hypromellose	Binder and film-coating polymer
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting agent and surface-active excipient
Talc	Anti-adherent and coating aid

[1]

The exact quantitative composition is proprietary. The listed excipients indicate a conventional high-performance tablet architecture rather than a modified-release system.

Why microcrystalline cellulose matters

Microcrystalline cellulose is likely important for tablet compactability and weight control. Eslicarbazepine acetate tablets must accommodate multiple strengths while maintaining acceptable hardness and disintegration. A cellulose-based diluent can support direct compression or dry granulation and is compatible with high-throughput manufacturing.

Commercial developers should evaluate particle size, bulk density, moisture content, and grade selection. A substitution between standard and silicified microcrystalline cellulose can materially change tablet tensile strength, ejection force, and dissolution.

Why croscarmellose sodium matters

Croscarmellose sodium promotes rapid water uptake and tablet breakup. Its performance depends on concentration, particle size, intragranular versus extragranular placement, and compression force.

Potential failure modes include:

• Slow disintegration caused by excessive compression
• Reduced wicking from over-lubrication
• Inconsistent dissolution after changing excipient grade
• Loss of performance at high tablet hardness

A generic developer should treat croscarmellose sodium as a critical material attribute rather than a freely interchangeable disintegrant.

Why sodium lauryl sulfate matters

Sodium lauryl sulfate can improve wetting of a poorly wettable drug substance and reduce dissolution variability. It can also affect powder flow, granulation behavior, tablet ejection, and stability.

Its presence creates a substitution issue. Removing or materially reducing the surfactant may preserve assay and content uniformity while causing a dissolution shift. A developer pursuing a simpler excipient system would need to demonstrate that the altered wetting profile does not change the biopharmaceutic performance of the product.

Why hypromellose and talc matter

Hypromellose and talc are commonly associated with film coating. The coating protects the tablet, supports color coding by strength, improves handling, and may reduce exposure to moisture and abrasion.

For a four-strength product, coating uniformity is commercially important. Strength-specific color identification reduces dispensing errors and supports pharmacy handling. A generic product can use a different coating system, but the visual presentation, tablet dimensions, and dissolution profile must remain suitable for the applicable regulatory pathway.

What excipient strategy is most suitable for an APTIOM generic?

The lowest-risk strategy is an excipient-matching approach using compendial, widely accepted excipients and a conventional immediate-release process.

Recommended generic platform

A practical platform would use:

1. Microcrystalline cellulose as the principal diluent and compression aid.
2. Croscarmellose sodium as the primary disintegrant.
3. Povidone only at the level required to control granule or tablet strength.
4. Magnesium stearate at a tightly controlled concentration and blending time.
5. A wetting agent where dissolution testing demonstrates a functional need.
6. A conventional hypromellose-based film coat.

The formulation should be developed across all four strengths rather than treating each strength as an independent product. A common blend with proportional tablet weights can reduce manufacturing complexity, but the 200 mg strength may require greater attention to content uniformity and tablet size.

Direct compression versus granulation

Direct compression offers lower processing cost, fewer unit operations, and reduced exposure to water and heat. It is attractive if the active pharmaceutical ingredient has suitable flow, bulk density, and compactability.

Dry granulation can improve flow and reduce segregation. It may be preferable when the drug substance has poor flow or when high-dose tablets require improved weight uniformity.

Wet granulation introduces additional process complexity and potential hydrolytic or solid-state risks. It should be used only when it provides a clear benefit in dissolution, content uniformity, or mechanical properties.

What formulation patents and intellectual-property opportunities exist?

The original APTIOM product is protected primarily through drug-substance, formulation, manufacturing, and method-of-use intellectual property rather than through a novel excipient alone. Excipient-related commercial protection is more likely to arise from a new dosage form, a defined release profile, a stability solution, or a patient-specific delivery system.

Potential formulation patent claims

Commercially relevant claim categories include:

• Eslicarbazepine acetate immediate-release compositions with defined dissolution ranges
• Low-moisture formulations that reduce degradation
• Specific particle-size distributions or polymorphic forms of the drug substance
• Film-coated tablets with improved stability or swallowability
• Orally disintegrating tablets
• Oral suspensions or reconstitutable powders
• Multiparticulate granules or sprinkle formulations
• Modified-release systems
• Fixed-dose combinations with another antiseizure medicine
• Pediatric dosage forms with taste-masking systems

An excipient combination is more defensible when it solves a measurable technical problem. Examples include improved dissolution at high drug loading, reduced tablet friability, improved stability under accelerated conditions, or acceptable taste in a liquid formulation.

A patent that claims only the presence of common excipients at broad concentration ranges would generally face a higher validity risk unless the formulation delivers an unexpected technical effect.

When does APTIOM lose exclusivity and what is the generic-entry profile?

APTIOM received U.S. approval in November 2013. Its five-year new chemical entity exclusivity period therefore reached its ordinary endpoint in November 2018. [2]

Patent-based market protection is separate from FDA exclusivity. The controlling commercial dates depend on the patents listed for APTIOM in the FDA Orange Book, any pediatric exclusivity attached to those patents or regulatory exclusivities, and the status of Paragraph IV litigation. [3]

APTIOM is a small-molecule drug, not a biologic. Biosimilar competition is therefore not applicable. Competitive entry occurs through abbreviated new drug applications, not biosimilar applications.

Paragraph IV challenge implications

An ANDA applicant may file a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. A patent-holder lawsuit filed within the statutory period can trigger a 30-month stay of final ANDA approval, subject to statutory exceptions and court developments. [4]

For APTIOM, the key commercial questions are:

• Which listed patents remain active?
• Do the claims cover the tablet composition, drug substance, method of treatment, or manufacturing process?
• Has a first filer obtained 180-day generic exclusivity?
• Has a settlement restricted or delayed launch?
• Does the ANDA use the same dosage form and strength architecture as the reference product?

A generic developer's risk is highest where the reference product retains active formulation or method-of-use patents that are difficult to design around. Risk is lower where the ANDA can rely on a same-label, same-dosage-form pathway and the remaining patents have limited claim scope.

What FDA regulatory pathway applies to APTIOM generics?

A conventional APTIOM tablet is generally suited to an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish pharmaceutical equivalence and bioequivalence to the reference listed drug. [5]

The critical development package normally includes:

• Drug-substance characterization
• Pharmaceutical equivalence
• Comparative dissolution
• Bioequivalence
• Impurity and degradation-product control
• Stability data
• Container-closure compatibility
• Manufacturing process validation
• Labeling that is the same as, or permitted to differ from, the reference labeling

A new oral liquid, orally disintegrating tablet, or modified-release product may require a 505(b)(2) application rather than a conventional ANDA, depending on dosage form, route, strength, labeling, and the extent of reliance on the reference product.

Excipient regulatory considerations

FDA’s Inactive Ingredient Database is the primary benchmark for prior use of excipients in approved drug products. [6] Developers should evaluate:

• Maximum daily exposure at the highest APTIOM dose
• Route-specific prior use
• Age-specific exposure for pediatric products
• Residual solvents and elemental impurities
• Nitrosamine risk from excipient and process interactions
• Peroxide content in excipients such as povidone or polymers
• Microbial limits for liquid products
• Preservative effectiveness for multidose suspensions

A pediatric liquid creates greater excipient scrutiny than a tablet because daily exposure to sweeteners, surfactants, preservatives, solvents, and viscosity modifiers must be justified against the intended age group.

What commercial opportunities exist for APTIOM excipient innovation?

Pediatric oral liquid

A pediatric liquid is the clearest unmet formulation opportunity. Tablets are less suitable for young children and patients with dysphagia. A liquid could expand use in the four-years-and-older population and improve dose titration.

The main technical challenge is taste. Eslicarbazepine acetate and its conversion products may require a combination of:

• Ion-exchange resin complexation
• Polymeric taste masking
• Sweetener and flavor systems
• Viscosity control
• A surfactant or wetting system
• Sedimentation control
• Preservative protection

A suspension may be more practical than a true solution if drug-solubility and stability constraints are substantial. A reconstitutable powder could reduce liquid stability risk and lower shipping weight.

Orally disintegrating tablet

An orally disintegrating tablet could address swallowing difficulty without requiring a liquid. Commercial differentiation would depend on rapid disintegration, acceptable mouthfeel, low friability, and taste masking.

The formulation could use mannitol, crospovidone, low-substituted hydroxypropyl cellulose, or specialized co-processed excipients. However, a high-dose 800 mg ODT would be difficult to manufacture at a commercially acceptable tablet size. The most viable approach may be lower-strength ODTs used in titration or combined dosing.

Sprinkle or multiparticulate formulation

Multiparticulates could be administered with soft food and may provide better pediatric usability than a conventional tablet. They also create an opportunity for taste masking and flexible dosing.

The main development issues are:

• Dose uniformity in a sachet or capsule
• Drug release after mixing with food
• Particle size and mouthfeel
• Stability after opening
• Packaging moisture protection
• Demonstration of bioequivalence

A sprinkle product may support a differentiated 505(b)(2) strategy if it cannot qualify as an ordinary tablet ANDA.

Modified-release product

A controlled-release eslicarbazepine product could reduce peak-related adverse effects or improve adherence. The commercial case is less straightforward because APTIOM is already dosed once daily. A modified-release product would need a clinically meaningful benefit over the existing schedule.

Potential technologies include hydrophilic matrix tablets, coated multiparticulates, osmotic systems, and gastroretentive systems. The patent opportunity would be stronger if the formulation produces a distinct exposure profile linked to improved tolerability or seizure control.

Excipient cost reduction

For standard generics, the most immediate opportunity is not a new excipient but a lower-cost and more robust process. Savings can come from:

• Direct compression instead of wet granulation
• Fewer excipient grades
• Common blend architecture across strengths
• Reduced coating weight
• Improved lubricant control
• Higher tablet press speed
• Lower rejection rates
• Simplified packaging

A cost-reduction program must preserve dissolution and bioequivalence. Magnesium stearate over-lubrication, altered cellulose grade, and changes in surfactant level are common sources of performance drift.

How strong is the APTIOM commercial opportunity?

APTIOM has a focused market rather than the scale of mass-market primary-care drugs. Its value is linked to chronic use, specialist prescribing, refill persistence, and the ability to reach patients who need an alternative to older antiseizure medicines.

Opportunity	Regulatory pathway	Technical difficulty	Commercial attractiveness
Conventional tablet generic	ANDA	Moderate	High for low-cost entrants
Pediatric oral suspension	ANDA or 505(b)(2)	High	High
Reconstitutable powder	505(b)(2) or product-specific pathway	High	Moderate to high
Orally disintegrating tablet	ANDA or 505(b)(2)	High	Moderate
Sprinkle multiparticulate	505(b)(2) or differentiated generic pathway	High	High in pediatrics
Modified-release tablet	505(b)(2)	Very high	Uncertain
Fixed-dose combination	505(b)(2) or new application	Very high	Depends on combination
Process-cost reduction	ANDA	Moderate	High for established generic manufacturers

The best risk-adjusted opportunity is a pediatric-friendly formulation with strong taste masking and dose flexibility. The best near-term manufacturing opportunity is a conventional tablet platform optimized for direct compression, blend uniformity, and high-throughput coating.

What manufacturing and IP barriers affect APTIOM products?

The main barriers are formulation reproducibility and regulatory equivalence rather than access to unusual excipients. Developers must control the relationship between drug-substance particle properties, excipient grade, compression force, lubricant exposure, disintegration, and dissolution.

Important manufacturing controls include:

• Drug-substance particle-size distribution
• Blend segregation during transfer
• Moisture uptake
• Lubrication time
• Tablet tensile strength
• Disintegration time
• Coating uniformity
• Dissolution across physiological pH conditions
• Stability under high temperature and humidity

For differentiated products, the intellectual-property barrier is stronger when the formulation uses a defined delivery system or produces a clinically relevant pharmacokinetic result. Common excipient combinations alone offer limited protection unless supported by unexpected performance data.

Key Takeaways

• APTIOM is an immediate-release eslicarbazepine acetate tablet available in four strengths.
• Its core excipient system uses microcrystalline cellulose, croscarmellose sodium, hypromellose, povidone, magnesium stearate, sodium lauryl sulfate, and talc.
• The highest-value formulation opportunity is a pediatric liquid, reconstitutable powder, or sprinkle product.
• A conventional tablet generic should prioritize excipient matching, dissolution robustness, and low-cost manufacturing.
• APTIOM received FDA approval in 2013, and ordinary five-year NCE exclusivity ended in 2018.
• Biosimilar competition does not apply because eslicarbazepine acetate is a small-molecule drug.
• Current generic-entry exposure depends on Orange Book patent listings, Paragraph IV certifications, litigation, settlements, and any remaining enforceable patent claims.
• The strongest new patent positions would likely involve taste masking, pediatric delivery, defined release profiles, or demonstrable stability and bioavailability improvements.

FAQs About APTIOM Excipient Strategy

Can APTIOM tablets be reformulated without sodium lauryl sulfate?

Yes, but the change may affect wetting and dissolution. A substitute formulation would require comparative dissolution and bioequivalence support.

Is an APTIOM oral suspension commercially feasible?

Yes. A suspension could address pediatric dosing and swallowing limitations, but taste masking, sedimentation, preservative control, and dose uniformity would be major development issues.

Which excipient is most important for APTIOM tablet disintegration?

Croscarmellose sodium is the principal listed superdisintegrant, although tablet hardness, lubricant level, cellulose grade, and compression conditions also control disintegration.

Would an APTIOM orally disintegrating tablet qualify as an ANDA?

Not automatically. The regulatory pathway would depend on whether the product can demonstrate equivalence to the reference listed drug in the proposed dosage form and whether differences require a 505(b)(2) application.

Does APTIOM have biosimilar risk?

No. APTIOM contains the small-molecule active ingredient eslicarbazepine acetate. Competitive products are regulated as generics or differentiated small-molecule products, not biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Aptiom (eslicarbazepine acetate) prescribing information. Sunovion Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (2024). New chemical entity exclusivity and regulatory exclusivity provisions. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of abbreviated new drug applications. FDA.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

6. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.